Jain B, Floreani A A, Anderson J R, Vose J M, Robbins R A, Rennard S I, Sisson J H
Pulmonary and Critical Care Medicine Section, University of Nebraska Medical Center, Omaha 68198-5300, USA.
Bone Marrow Transplant. 1996 Apr;17(4):561-8.
Cardiopulmonary complications are a major cause of morbidity and mortality in patients undergoing high-dose therapy with stem cell transplant support. Since exercise tolerance testing (ETT) assesses the cardiopulmonary reserve of an individual, we hypothesized that ETT performed prior to transplant would predict respiratory failure and mortality and would be a superior predictor over resting cardiopulmonary function tests. We performed a retrospective study of 191 lymphoma patients who underwent ETT prior to transplant between 1 June 1990 and 31 December 1992 and compared the results of ETT with resting pulmonary function tests (PFT) and resting cardiac ejection fraction (EF). ETT revealed that cardiac, pulmonary and combined cardiopulmonary limitation were observed in 31, 20 and 16% of the patients, respectively, with a gas diffusion-type limitation being the most common exercise limitation. Resting PFT were abnormal in 58% of patients with a diffusion defect being the most common abnormality. Low EF was observed in 6.8% of patients. Twelve patients eventually required mechanical ventilation post-transplant with only the resting diffusion PFT predictive of this complication. There were five early deaths that were attributable to respiratory failure and neither resting nor ETT studies were predictive of these deaths. ETT and EF performed prior to transplant in lymphoma patients undergoing autologous transplant do not predict for either respiratory failure or short-term mortality. Our findings may be due to the rather low incidence of respiratory failure (6.3%) and low early mortality from cardiopulmonary complications (2.6%) seen in our patient population.
心肺并发症是接受高剂量疗法并伴有干细胞移植支持的患者发病和死亡的主要原因。由于运动耐量测试(ETT)可评估个体的心肺储备能力,我们推测移植前进行的ETT能够预测呼吸衰竭和死亡率,并且相较于静息心肺功能测试,它是一个更优的预测指标。我们对1990年6月1日至1992年12月31日期间191例移植前接受ETT的淋巴瘤患者进行了一项回顾性研究,并将ETT结果与静息肺功能测试(PFT)和静息心脏射血分数(EF)进行了比较。ETT结果显示,分别有31%、20%和16%的患者存在心脏、肺部及心肺联合功能受限,其中气体扩散型受限是最常见的运动受限类型。58%的患者静息PFT异常,其中扩散功能缺陷是最常见的异常情况。6.8%的患者出现低EF。12例患者移植后最终需要机械通气,只有静息扩散PFT可预测这一并发症。有5例早期死亡归因于呼吸衰竭,静息研究和ETT均无法预测这些死亡。接受自体移植的淋巴瘤患者移植前进行的ETT和EF均无法预测呼吸衰竭或短期死亡率。我们的研究结果可能是由于我们的患者群体中呼吸衰竭发生率较低(6.3%)以及心肺并发症导致的早期死亡率较低(2.6%)。